Inebilizumab, an anti-CD19+ (B cell)mAb was tested in myasthenia gravis in phase 3, 238 pt trial and shows to signif. improv function and reduce disease severity in acetylcholine recpt Ab+ or muscle-specific kinase Ab+ myasthenia gravis pts. https://t.co/vBBjf8AUug https://t.co/cUbK4PJEvf
Links:
A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis | NEJM
https://buff.ly/Y5PBzWb
Apr-10-2025
